written by reader JEFF BROWN RECENT TEASER

By alas, April 27, 2020

FOR EXPONENTIAL TECH, regarding a small biotech:
”In July 2018, this biotech announced positive results for its Phase 1 clinical trials. And get this. This drug has been used for many years in Japan with few adverse side effects.
Because of this, the FDA granted the drug a qualified infectious disease product designation. In other words, the FDA allowed the company to skip Phase 2 trials and move directly into Phase 3.”
”It’s 2020… and antibacterial infections are killing people at a rate similar to the Middle Ages.
Yet we’re using antibiotics made in the 1980s to treat them. These antibiotics are terribly ineffective today. Even dangerous to rely on.
The CDC warns that 2.8 million Americans will be affected just this year.
It’s why the FDA fast-tracked the approval of the most powerful antibiotic in nearly 40 years.”

Any idea what company this is?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

14 Comments
Inline Feedbacks
View all comments
btjossem
Irregular
btjossem
April 27, 2020 11:45 am

I have been researching this and haven’t gotten terribly far, but thought I would throw this 1 out.
https://www.marketbeat.com/stocks/NASDAQ/SPRO/
Spero therapeutics
I got here because it was listed as a company that Google has invested in.
That was mentioned in Jeff Brown’s audio (that I finally had to stop listening to… LONG, AS USUAL)
the current market Cap: $204 million
I think Jeff indicated it was $180 million
pretty close.
It’s up about 18% today, 4/27.
I still haven’t determined if they have a drug that has skipped phase 2.

👍 87
David
Guest
David
April 27, 2020 12:04 pm
Reply to  btjossem

Spero (SPRO) does have a pipeline that is focused on multi-drug resistant (MDR) pathogens. They have several trials in progress and recently received orphan drug status for SPR720 which treats nontuberculous myobacterial infections.

They also just appointed Scott Jackson to BoD. He was CEO of Celator Pharm. until it was acquired by Jazz Pharma.

Add a Topic
10783
Add a Topic
6038
Add a Topic
2693
samwiebaux
Guest
samwiebaux
April 27, 2020 1:19 pm

TRAVIS, WHAT ABOUT JEFF HOWARD’S BIOTECH, STAGE 3, OUT OF MASSACHUSETTS – ANY IDEA WHAT IT IS???

👍 65
samwiebaux
Guest
samwiebaux
April 27, 2020 1:27 pm

I just posted this. (Spero Therapeutics, us military, antibiotic trials) Came up with SPERO ! I BELIEVE THIS MAY BE IT! ABOUT $10

David
Guest
David
April 27, 2020 3:53 pm
Reply to  samwiebaux

SPRO is up about 20% today. Institutional ownership is ~48%. No insider trades reported since 2018. Insiders own ~18%. This has definitely been a pump today. It will be curious to see if they follow with an offering.

Add a Topic
10783
Dave
Member
Dave
April 27, 2020 10:05 pm
Reply to  David

what kind of offering do you suspect?